VERIGRAFT awarded Arvid Carlsson Award 2025 for groundbreaking advances in regenerative medicine
VERIGRAFT awarded Arvid Carlsson Award 2025 for groundbreaking advances in regenerative medicine
Life science company Verigraft is this year's recipient of the Arvid Carlsson Award 2025 for its innovative technology that enables patient-tailored transplants without the need for immunosuppression.
"This award is a significant recognition of our team's hard work and the potential of personalized regenerative therapy,” says Petter Björquist , CEO of Verigraft.
Sahlgrenska Science Park annually presents the Arvid Carlsson Award to an actor who, through innovation and science, contributes to the development of future health. This year's recipient, Verigraft, has developed a regenerative medicine platform that makes it possible to convert donated tissue into personalized transplants. The technology eliminates the risk of rejection and reduces the need for lifelong immunosuppression - factors that can improve recovery and quality of life for patients with serious medical conditions.
–Verigraft shows how research, courage and innovative power can be translated into solutions that make a difference in healthcare. Their work reflects the spirit of scientific renewal that Arvid Carlsson stood for, says Cecilia Edebo, CEO of Sahlgrenska Science Park.
The technology has already been evaluated in initial clinical studies and is now being further developed for application in cardiovascular diseases. Verigraft's work represents the type of translational development – from research to clinical use – that Arvid Carlsson himself advocated.
– We are honored that our research and clinical progress are recognized through the Arvid Carlsson Award. The award gives us further motivation to continue developing treatments that can change the lives of patients with severe, chronic diseases and in need of advanced therapy, says Petter Björquist.
About Arvid Carlsson
Arvid Carlsson (1923–2018) was a Swedish physician, pharmacologist and Nobel Prize laureate in Physiology or Medicine in 2000. He was awarded for his groundbreaking discoveries about the neurotransmitter dopamine and its importance for brain function, and his research led to the development of new treatment principles for several neurological and psychiatric diseases, including Parkinson's disease.
Arvid Carlsson was active at the University of Gothenburg and the Sahlgrenska Academy and is internationally recognized as one of Sweden's most influential researchers of all time. His work was characterized by scientific curiosity, perseverance and the conviction that research should be translated into practical benefit for patients, values that form the basis of the Arvid Carlsson Award.
Read the Swedish Press Release
